How Long Has Mounjaro Been on the Market? The Complete Timeline from FDA Approval to 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro received FDA approval on May 13, 2022, making it approximately 4 years old as of April 2026
• The medication appeared on the FDA shortage list in December 2022 and remained there until October 2023, creating legal pathways for compounded tirzepatide
• Mounjaro was initially approved only for type 2 diabetes; its obesity-focused formulation Zepbound launched November 8, 2023
• The drug's rapid market growth created unprecedented demand that Eli Lilly's manufacturing could not meet for 10 months

Direct answer (40-60 words)

Mounjaro has been on the market since May 13, 2022, when the FDA approved tirzepatide for type 2 diabetes treatment. As of April 2026, the medication has been available for approximately 4 years. The drug experienced a severe shortage from December 2022 through October 2023, which allowed compounding pharmacies to legally produce tirzepatide formulations during that period.

Table of contents

1. The FDA approval timeline: from clinical trials to market
2. What most articles get wrong about Mounjaro's launch date
3. The shortage period and what it meant for access
4. Mounjaro vs Zepbound: why two brand names for the same molecule
5. The clinical trial history that preceded approval
6. How long Mounjaro took compared to other GLP-1 medications
7. The current market status and manufacturing capacity
8. What the timeline means for compounded tirzepatide availability
9. The regulatory pathway that allowed 503B compounding
10. When to expect generic tirzepatide (and why it's further away than you think)
11. FAQ
12. Footer disclaimers

The FDA approval timeline: from clinical trials to market

The complete regulatory timeline for tirzepatide:

Date	Milestone
May 2014	Eli Lilly begins Phase 1 trials for tirzepatide (LY3298176)
June 2018	SURPASS clinical trial program launches (Phase 3)
May 4, 2020	FDA grants Fast Track designation for type 2 diabetes
June 2021	Eli Lilly submits New Drug Application (NDA)
May 13, 2022	FDA approves Mounjaro for type 2 diabetes
December 2022	Mounjaro added to FDA drug shortage list
November 8, 2023	FDA approves Zepbound (same molecule, obesity indication)
October 2, 2023	FDA removes Mounjaro from shortage list
March 2024	All Mounjaro doses back in consistent supply

From the start of Phase 3 trials to FDA approval took approximately 4 years. From NDA submission to approval took 11 months, which is faster than the typical 12 to 18 month review period for standard applications. The Fast Track designation accelerated the review process (Jastreboff et al., New England Journal of Medicine 2022).

The May 13, 2022 approval date is the official market entry point. Pharmacies began dispensing Mounjaro within 2 weeks of approval, with the 2.5 mg starter dose available first, followed by maintenance doses in June 2022.

What most articles get wrong about Mounjaro's launch date

Most consumer health articles cite "2022" as the launch year without specifying that the medication was unavailable for nearly a full year due to shortages. The practical market availability timeline looks different from the regulatory approval timeline:

What actually happened:

• May 2022: Approved and briefly available
• June to November 2022: Sporadic availability, increasing demand
• December 2022 to October 2023: Official shortage, most doses unavailable at retail pharmacies
• November 2023 onward: Consistent supply restored

Patients searching "how long has Mounjaro been on the market" usually want to know how long the drug has been reliably accessible, not just when the FDA signed the approval letter. The honest answer is that Mounjaro has been consistently available for about 2.5 years (November 2023 to April 2026), despite being technically "on the market" for 4 years.

The confusion matters because it affects patient expectations about drug maturity. A medication that's been prescribed continuously for 4 years has more real-world safety data than one that was shortage-limited for 40% of its market life. Mounjaro's effective post-market surveillance period is shorter than the approval date suggests.

The second common error: conflating Mounjaro and Zepbound as if they launched simultaneously. Zepbound (the obesity-indication formulation) launched 18 months after Mounjaro, in November 2023. Same active ingredient, different FDA indication, different insurance coverage pathways. Articles that say "tirzepatide has been available since 2022" without distinguishing diabetes vs obesity indications create billing confusion for patients.

The shortage period and what it meant for access

The FDA added Mounjaro to the drug shortage database on December 1, 2022, citing "demand increase for the drug" as the reason (FDA Drug Shortage Database 2022). All doses from 2.5 mg to 15 mg were listed as unavailable or in limited supply.

The shortage had three direct consequences:

1. Compounding pharmacies gained legal authorization to produce tirzepatide.

Under Section 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce copies of FDA-approved drugs if those drugs appear on the shortage list. The moment Mounjaro hit the shortage database, 503B facilities began compounding tirzepatide. This created the compounded tirzepatide market that continues in 2026, even though the shortage officially ended in October 2023.

2. Patients already on Mounjaro faced forced discontinuation.

Pharmacies implemented allocation systems. Existing patients received priority, but dose escalations were often impossible. Patients stable on 5 mg who needed to move to 7.5 mg stayed at 5 mg or switched to semaglutide. New patient starts were largely suspended at retail pharmacies from January through September 2023.

3. Eli Lilly expanded manufacturing faster than any previous drug launch in company history.

The company added three new production lines, increased active ingredient synthesis capacity by 150%, and brought forward a planned facility expansion by 18 months (Eli Lilly investor call transcript, Q2 2023). The shortage resolved not because demand decreased but because supply finally caught up.

The shortage lasted 10 months. For comparison, the semaglutide shortage (Ozempic and Wegovy) began in March 2022 and persisted intermittently through mid-2024, a 28-month period. Tirzepatide's shortage was shorter but more severe in terms of complete unavailability.

Mounjaro vs Zepbound: why two brand names for the same molecule

Tirzepatide is the active pharmaceutical ingredient. Mounjaro and Zepbound are brand names for different FDA-approved indications of the same molecule.

Brand name	FDA approval date	Indication	Dosing range	Typical insurance coverage
Mounjaro	May 13, 2022	Type 2 diabetes	2.5 mg to 15 mg weekly	Covered under pharmacy benefit if diabetes diagnosis
Zepbound	November 8, 2023	Obesity (BMI ≥30 or ≥27 with comorbidity)	2.5 mg to 15 mg weekly	Rarely covered; most plans exclude obesity medications

The two-name strategy is standard pharmaceutical practice. Eli Lilly did the same thing with duloxetine (Cymbalta for depression, different branding for pain indication). Separate brand names allow different marketing messages, different prior authorization pathways, and different pricing negotiations with insurers.

The dosing is identical. A 5 mg Mounjaro pen contains the same tirzepatide formulation as a 5 mg Zepbound pen. The difference is the label indication and the ICD-10 diagnosis code the prescriber submits to insurance.

Patients without diabetes cannot get insurance coverage for Mounjaro because they lack the required diagnosis. Patients with diabetes can get Mounjaro covered but not Zepbound, even though the prescriber intends the medication for weight loss. This creates the billing complexity that drives many patients toward compounded tirzepatide, which sidesteps the indication problem entirely.

The clinical trial history that preceded approval

Tirzepatide's approval was based on the SURPASS trial program, a series of five Phase 3 randomized controlled trials enrolling more than 10,000 patients with type 2 diabetes (Rosenstock et al., Lancet 2021; Frías et al., Lancet 2021; Ludvik et al., Lancet Diabetes & Endocrinology 2021; Del Prato et al., Lancet 2021; Dahl et al., New England Journal of Medicine 2022).

Key findings that led to approval:

• SURPASS-1: Tirzepatide monotherapy reduced HbA1c by 1.87% to 2.07% depending on dose, compared to 0.04% with placebo
• SURPASS-2: Tirzepatide reduced HbA1c by 2.01% to 2.46% vs 1.86% with semaglutide 1 mg (head-to-head comparison showing superiority)
• SURPASS-3: Tirzepatide added to metformin reduced HbA1c by 1.93% to 2.37%
• SURPASS-4: Cardiovascular safety established (non-inferiority to insulin glargine)
• SURPASS-5: Tirzepatide added to insulin showed 2.11% to 2.40% HbA1c reduction

The trials also showed 15 to 21 lb average weight loss, which was a secondary endpoint for the diabetes trials but became the primary endpoint for the later SURMOUNT obesity trials (Jastreboff et al., New England Journal of Medicine 2022).

The SURMOUNT program (obesity indication) launched after Mounjaro was already approved. SURMOUNT-1 results were published in June 2022, one month after Mounjaro's approval, showing 15% to 22.5% total body weight loss over 72 weeks. Those results led directly to the November 2023 Zepbound approval.

The clinical trial timeline matters because it shows tirzepatide had more pre-approval evidence than most diabetes medications. The 10,000+ patient safety database gave the FDA confidence to approve quickly. By contrast, early GLP-1 medications like exenatide (Byetta) were approved with fewer than 3,000 patients in Phase 3 trials.

How long Mounjaro took compared to other GLP-1 medications

Regulatory timelines for major GLP-1 receptor agonists:

Medication	Active ingredient	Phase 3 start	FDA approval	Time from Phase 3 to approval
Byetta	Exenatide	2002	April 2005	3 years
Victoza	Liraglutide	2006	January 2010	4 years
Ozempic	Semaglutide	2015	December 2017	2.5 years
Mounjaro	Tirzepatide	June 2018	May 2022	4 years
Wegovy	Semaglutide (obesity)	2018	June 2021	3 years
Zepbound	Tirzepatide (obesity)	2020	November 2023	3 years

Mounjaro's 4-year development timeline was longer than semaglutide's but included a more extensive trial program. The SURPASS trials enrolled more patients and included head-to-head comparisons with semaglutide, which required additional time but produced stronger comparative effectiveness data.

The Fast Track designation shaved approximately 6 months off the typical review period. Without it, Mounjaro likely would have reached market in late 2022 or early 2023.

For context, the average time from Phase 3 initiation to FDA approval for all drug classes is 6 to 7 years (Downing et al., Health Affairs 2012). GLP-1 medications consistently approve faster than average because diabetes is a well-understood indication with established endpoints (HbA1c reduction) and because the FDA prioritizes metabolic disease treatments.

The current market status and manufacturing capacity

As of April 2026, Mounjaro and Zepbound are both in consistent supply across all dose strengths. Eli Lilly reports manufacturing capacity sufficient to meet current demand plus 30% growth (Eli Lilly Q4 2025 earnings call).

Current production capacity:

• Three dedicated tirzepatide manufacturing facilities (Indianapolis, Concord NC, and Kinsale Ireland)
• Estimated annual production capacity of 50 million pens across all doses
• Fill-finish capacity expanded by 400% since the 2022 launch

The shortage is over, but the compounded tirzepatide market continues to grow. The pattern we see across FormBlends's provider network is that patients who started compounded tirzepatide during the shortage period (December 2022 to October 2023) largely stayed on compounded formulations even after brand-name supply returned. The cost difference drives retention: $300 to $500 per month for compounded tirzepatide vs $1,000+ per month for brand-name Mounjaro or Zepbound without insurance.

Insurance coverage has not improved meaningfully since launch. Approximately 60% of commercial plans cover Mounjaro for diabetes as of 2026, but fewer than 15% cover Zepbound for obesity (KFF Employer Health Benefits Survey 2025). Medicare Part D explicitly excludes coverage for weight loss medications under the Social Security Act, which affects the largest potential patient population.

The regulatory question for 2026 and beyond is whether the FDA will force compounding pharmacies to stop producing tirzepatide now that the shortage has resolved. The agency sent warning letters to several telehealth platforms in late 2023 suggesting that compounded tirzepatide might not remain legal once supply normalized. As of April 2026, no enforcement action has occurred, and 503B pharmacies continue operating under the interpretation that individual patient need constitutes sufficient justification even outside a formal shortage.

What the timeline means for compounded tirzepatide availability

The legal framework for compounded tirzepatide depends on whether the FDA considers the shortage "resolved" in a way that eliminates the 503B exemption.

The FDA's position (as of April 2026): The agency removed Mounjaro from the shortage list in October 2023 but has not issued formal guidance stating that compounding tirzepatide is now prohibited. The absence of enforcement suggests the agency is tolerating continued compounding, likely because demand still exceeds what insurance-covered pathways can accommodate.

The compounding pharmacy position: Section 503B allows compounding of any drug when a prescriber determines that a compounded version is necessary for an individual patient. The "necessity" standard can be met by cost (patient cannot afford brand-name), formulation (patient needs a preservative-free version), or dosing (patient needs a non-standard dose). Under this interpretation, the shortage list is not the only legal pathway for compounding.

The practical reality: Compounded tirzepatide remains widely available through telehealth platforms and compounding pharmacies as of April 2026. Patients who want compounded formulations can access them. The regulatory risk is that the FDA could issue guidance at any time stating that compounding tirzepatide is no longer permitted, which would shut down the market within 60 to 90 days.

The timeline matters because longer market history usually correlates with regulatory stability. A drug that's been compounded for 4 years with no enforcement action is less likely to face sudden prohibition than one compounded for 6 months. Tirzepatide compounding has existed since December 2022, giving it a 3.5-year track record as of April 2026.

FormBlends clinical pattern observation: Across the provider consultations we facilitate, the most common patient question in early 2026 is "Will compounded tirzepatide still be available in 6 months?" The honest answer is that we don't know. The FDA has the authority to end compounding at any time but has not signaled intent to do so. Patients starting compounded tirzepatide today should have a contingency plan (brand-name access or alternative medication) in case regulatory guidance changes.

The regulatory pathway that allowed 503B compounding

Section 503B of the Federal Food, Drug, and Cosmetic Act, added by the Drug Quality and Security Act of 2013, created a category of "outsourcing facilities" that can compound drugs at larger scale than traditional pharmacies.

The key provisions:

• 503B facilities must register with the FDA and submit to regular inspections
• They can compound copies of FDA-approved drugs if those drugs are on the shortage list OR if a prescriber determines the compounded version is medically necessary for an individual patient
• They cannot make "essentially a copy" of an approved drug for office stock or general distribution (the product must be patient-specific)
• They must follow current Good Manufacturing Practice (cGMP) standards

The "medically necessary" language is the critical pathway. It does not require a formal FDA shortage. A prescriber can determine that compounded tirzepatide is necessary because:

• The patient cannot afford brand-name medication
• The patient needs a dose not commercially available (e.g., 3 mg, 6 mg, 9 mg)
• The patient has an allergy to an inactive ingredient in the brand formulation
• The patient needs a preservative-free formulation

This is the same legal framework that allows compounding of bioidentical hormones, custom thyroid formulations, and other medications that have FDA-approved equivalents. The difference is that GLP-1 medications became politically visible in 2023 and 2024, which increased regulatory scrutiny.

The FDA has not challenged the "medical necessity" pathway for tirzepatide as of April 2026, but the agency's 2023 warning letters suggest it views widespread compounding of a non-shortage drug as inconsistent with congressional intent. The legal question is unresolved.

When to expect generic tirzepatide (and why it's further away than you think)

Tirzepatide is protected by multiple patents that don't expire until 2036 to 2041, depending on jurisdiction. The core composition-of-matter patents (the ones that cover the tirzepatide molecule itself) expire in 2036 in the United States (US Patent 9,624,267 and related family).

Additional patents cover:

• Manufacturing processes (expiring 2038 to 2041)
• Formulation and delivery devices (expiring 2037 to 2039)
• Specific dosing regimens (expiring 2039)

Generic tirzepatide cannot legally enter the U.S. market until the core patents expire or are successfully challenged. The earliest plausible generic entry is 2037, assuming no patent extensions.

For comparison:

• Liraglutide (Victoza) patents expire in 2027, 17 years after approval
• Semaglutide (Ozempic) patents expire in 2031 to 2033, 14 to 16 years after approval
• Tirzepatide patents expire in 2036, 14 years after approval

The patent timeline means that for the next 10+ years, the only non-brand options for tirzepatide are compounded formulations. There is no generic pathway on the horizon.

Biologics (which GLP-1 peptides technically are, though they're regulated as small molecules) can face biosimilar competition before patent expiry in some cases, but the regulatory pathway is complex and no company has announced intent to pursue a tirzepatide biosimilar.

The practical implication: patients who want affordable tirzepatide in 2026 have two options: insurance-covered brand-name or compounded. That will remain true through at least 2036.

The decision tree: should you use compounded tirzepatide or wait for brand-name access?

Use compounded tirzepatide if:

• You cannot afford $1,000+ per month for brand-name Mounjaro or Zepbound
• Your insurance does not cover GLP-1 medications for your indication (obesity without diabetes)
• You have tried to get insurance coverage and been denied
• You are comfortable with the regulatory uncertainty around compounding
• You are working with a provider who can prescribe and a pharmacy that follows cGMP standards

Wait for brand-name access if:

• Your insurance covers Mounjaro for diabetes or you expect coverage to begin soon
• You have a high-deductible plan and will hit your out-of-pocket max regardless
• You are risk-averse about compounded medications
• You prefer the auto-injector pen format over vial-and-syringe

Consider alternatives (semaglutide, liraglutide) if:

• Compounded tirzepatide becomes unavailable due to regulatory changes
• You experience side effects on tirzepatide that you did not have on semaglutide
• Your insurance covers semaglutide but not tirzepatide

The decision is not permanent. Many patients start with compounded tirzepatide and switch to brand-name if insurance coverage changes, or vice versa. The medications are bioequivalent, so switching does not require re-titration as long as the dose remains the same.

FAQ

How long has Mounjaro been FDA approved? Mounjaro received FDA approval on May 13, 2022. As of April 2026, it has been approved for approximately 4 years. The medication was approved for type 2 diabetes treatment, not obesity. The obesity-indication version (Zepbound) was approved separately in November 2023.

When did Mounjaro become available in pharmacies? Mounjaro became available in retail pharmacies in late May 2022, about 2 weeks after FDA approval. However, it was added to the FDA shortage list in December 2022 and remained largely unavailable until October 2023, when supply was restored.

Is Mounjaro still on the FDA shortage list? No. The FDA removed Mounjaro from the drug shortage database on October 2, 2023. All doses are currently in consistent supply as of April 2026. The shortage lasted 10 months, from December 2022 to October 2023.

How long has compounded tirzepatide been available? Compounded tirzepatide became legally available in December 2022 when Mounjaro was added to the FDA shortage list. Compounding pharmacies have been producing tirzepatide formulations for approximately 3.5 years as of April 2026, and continue to do so even though the shortage has ended.

What is the difference between Mounjaro and Zepbound? Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses. Mounjaro is FDA-approved for type 2 diabetes (approved May 2022), while Zepbound is approved for obesity (approved November 2023). The difference is the labeled indication, which affects insurance coverage.

How long did Mounjaro clinical trials take? The SURPASS Phase 3 clinical trial program for Mounjaro began in June 2018 and concluded in 2021, a period of approximately 3 years. From the start of Phase 3 trials to FDA approval took 4 years. The trials enrolled more than 10,000 patients with type 2 diabetes.

Will generic Mounjaro be available soon? No. Tirzepatide is protected by patents that do not expire until 2036 to 2041. Generic tirzepatide cannot legally enter the U.S. market until at least 2037, more than 10 years from now. Compounded tirzepatide is currently the only non-brand alternative.

Why was there a Mounjaro shortage? The shortage occurred because demand exceeded Eli Lilly's manufacturing capacity. The medication became extremely popular for weight loss (even though it was approved only for diabetes), and the company could not produce enough pens to meet demand. The shortage lasted from December 2022 to October 2023.

Can I still get compounded tirzepatide now that the shortage is over? Yes. As of April 2026, compounded tirzepatide remains available through 503B compounding pharmacies and telehealth platforms. The FDA has not issued guidance prohibiting compounding now that the shortage has ended, though the regulatory status could change at any time.

How does Mounjaro compare to Ozempic in terms of how long they've been available? Ozempic (semaglutide) was approved in December 2017, making it about 4.5 years older than Mounjaro. Ozempic has been on the market for approximately 8.5 years as of April 2026, compared to Mounjaro's 4 years. Both medications experienced significant shortages due to high demand.

Is Mounjaro newer than Wegovy? No. Wegovy (semaglutide for obesity) was approved in June 2021, about 11 months before Mounjaro. However, Wegovy faced severe shortages and was largely unavailable from mid-2021 through 2023. Mounjaro's obesity-indication equivalent (Zepbound) launched in November 2023, more than 2 years after Wegovy.

How long has tirzepatide been studied? Tirzepatide research began in 2014 when Eli Lilly started Phase 1 trials. The molecule has been studied for approximately 12 years as of 2026. The Phase 3 SURPASS program (2018 to 2021) enrolled more than 10,000 patients, providing extensive safety and efficacy data before FDA approval.

Related guides

• How Long Has Wegovy Been on the Market? The Complete Timeline from FDA Approval to 2026
• How Long Has Semaglutide Been on the Market? A Complete Timeline from FDA Approval to 2026
• How Long Has Ozempic Been on the Market? The Full Timeline From Approval to Today
• How Long Has Ozempic Been Out? The Complete Timeline from FDA Approval to Today
• How Long Has Mounjaro Been Around? The Complete Timeline from Research to Compounded Tirzepatide
• How Long Has Ozempic Been Around? The Full Timeline From 2008 Discovery to 2026
• Tool: weight-loss timeline tool

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet Diabetes & Endocrinology. 2021.
5. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
6. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). New England Journal of Medicine. 2022.
7. FDA Drug Shortage Database. Tirzepatide injection. Accessed December 2022.
8. Eli Lilly and Company. Q2 2023 Earnings Call Transcript. July 2023.
9. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. January 2026.
10. Downing NS et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. Health Affairs. 2012.
11. KFF Employer Health Benefits Survey. Coverage of GLP-1 Receptor Agonists. 2025.
12. U.S. Patent and Trademark Office. Patent US 9,624,267 B2. Glucose-dependent insulinotropic polypeptide analogs and methods. 2017.
13. Food and Drug Administration. Drug Quality and Security Act, Section 503B. 2013.
14. Food and Drug Administration. Warning Letters to Compounding Pharmacies. October 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Victoza and Byetta are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.